Welcome to our dedicated page for Vanda Pharma news (Ticker: VNDA), a resource for investors and traders seeking the latest updates and insights on Vanda Pharma stock.
Vanda Pharmaceuticals Inc. (VNDA) is a biopharmaceutical innovator developing therapies for complex medical conditions with limited treatment options. This news hub provides investors and healthcare professionals with essential updates on the company's clinical advancements, regulatory milestones, and strategic initiatives.
Access real-time information about VNDA's sleep-wake disorder treatments, psychiatric therapies, and neurology pipeline. Our curated collection includes FDA decision updates, clinical trial results, financial earnings reports, and partnership announcements – all critical for understanding the company's market position.
Bookmark this page for streamlined tracking of Vanda's progress in antisense oligonucleotide research and commercialization efforts. Regular updates ensure you stay informed about HETLIOZ developments, Fanapt market performance, and emerging therapies in the company's clinical pipeline.
Vanda Pharmaceuticals (Nasdaq: VNDA) announced its participation in significant investor conferences this November, including the Stifel 2021 Virtual Healthcare Conference on November 15, 2021, and the Jefferies 2021 London Healthcare Conference on November 18-19, 2021. A corporate presentation will be available at the Stifel conference, while an on-demand fireside chat will be accessible for the Jefferies event. Investors can access presentations via Vanda's website, with archived content available for 30 days post-event.
Vanda Pharmaceuticals (VNDA) reported strong financial growth in Q3 2021, with total product sales of $70.1 million, a 16% increase from $60.3 million in Q3 2020. HETLIOZ® sales rose 15% to $45.6 million, while Fanapt® sales climbed 18% to $24.5 million. Net income reached $7.8 million, up from $5.9 million year-over-year. However, Vanda revised its HETLIOZ® sales guidance downward due to escalating reimbursement challenges, now estimating $170 to $190 million for 2021. The company anticipates results from a pivotal Phase III study on tradipitant in gastroparesis by year-end.
Vanda Pharmaceuticals Inc. (Nasdaq: VNDA) will announce its third quarter 2021 financial results on November 3, 2021, after market close. A conference call will follow at 4:30 PM ET, where management will discuss the results and corporate activities. Investors can join the call by dialing 1-866-688-9426 domestically or 1-409-216-0816 internationally, with passcode 5961858. The call will also be accessible via Vanda's website and available for replay starting at 7:30 PM ET on the same day until November 10, 2021.
Vanda Pharmaceuticals (Nasdaq: VNDA) has announced its participation in Evercore ISI's Catalyst Day on October 18, 2021. CEO Mihael H. Polymeropoulos will engage in a virtual fireside chat at 1:30 PM ET. Vanda Pharmaceuticals focuses on developing innovative therapies for unmet medical needs. For further details, visit www.vandapharma.com.
Vanda Pharmaceuticals Inc. (VNDA) announced its participation in the Citi 16th Annual BioPharma Virtual Conference from September 8 to September 10, 2021. The company's management will conduct investor meetings during the event. Vanda has also updated its corporate presentation, available on its website under the Investors tab. Vanda Pharmaceuticals is dedicated to developing innovative therapies to meet significant medical needs.
Vanda Pharmaceuticals (Nasdaq: VNDA) has announced the closure of enrollment in the ODYSSEY study, which aimed to compare tradipitant and placebo in hospitalized COVID-19 pneumonia patients. The study was terminated after meeting pre-defined futility criteria, suggesting it was unlikely to achieve its primary endpoint of treatment efficacy. A total of 153 patients were enrolled against a goal of 324. Despite this, Vanda will proceed with genetic analysis to explore susceptibility factors related to severe pneumonia in COVID-19 patients.
Vanda Pharmaceuticals (Nasdaq: VNDA) reported Q2 2021 financial results with total net product sales reaching $67.9 million, a 9% increase year-over-year. HETLIOZ® sales grew 7% to $44.5 million, while Fanapt® saw a 13% increase to $23.4 million. Net income was $9.7 million, up from $8.7 million in Q2 2020. For the first half of 2021, total sales rose 9% to $130.6 million, and cash reserves were $396.5 million. The Phase III trial of tradipitant for gastroparesis is nearing completion, with results expected by year-end 2021.
Vanda Pharmaceuticals (Nasdaq: VNDA) will release its second quarter 2021 financial results on July 28, 2021, after market close. A conference call is scheduled for 4:30 PM ET the same day to discuss the results and corporate activities. Investors can access the call by dialing 1-866-688-9426 for domestic calls or 1-409-216-0816 internationally. The call will also be available on the company's website, with a replay option from 7:30 PM ET on July 28 until 7:30 PM ET on August 4, 2021.
Vanda Pharmaceuticals Inc. (Nasdaq: VNDA) announced its management will participate in upcoming investor conferences. These include the Bank of America Securities 2021 Virtual Health Care Conference on May 13, 2021, Oppenheimer Virtual Rare & Orphan Disease Summit on May 21, 2021, and Jefferies Virtual Healthcare Conference on June 2, 2021. Investors can access the conferences via the company's corporate website, with archive links available for 30 days post-event. Vanda focuses on developing therapies to address significant medical needs.
Vanda Pharmaceuticals (Nasdaq: VNDA) reported strong first-quarter results for 2021, with total net product sales reaching $62.7 million, an 8% increase year-over-year. Key revenue contributors included HETLIOZ® at $39.3 million (up 11%) and Fanapt® at $23.3 million (up 3%). The company achieved an income before taxes of $10.4 million compared to $1.2 million in 2020. Vanda also provided 2021 guidance, forecasting total revenues between $270 million and $300 million.
